RGFP966
RGFP966 is specific for HDAC3, with an IC50 of 0.08 µM and no effective inhibition of any other HDAC at concentrations up to 15 µM.
Product Specifications
Background
RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor. RGFP966 treatment on two CTCL cell lines for 24 hours prior to Western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression.
CAS Number
1357389-11-7
Solubility
Soluble in DMSO
Molecular Formula
C21H19FN4O
Shipping Conditions
Room Temperature (continental US) or Gel Packs
Storage Conditions
Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Calculated Molecular Weight
362.4 Da
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15351771 1 Vial
Lentiviral human SOX18 shRNA (UAS) - Lentiviral human SOX18 shRNA (UAS, RFP) (100)
Sign In for Pricing
View Details 
ARP74496_P050-Biotin 100 µL
DRG1 Antibody - middle region : Biotin (ARP74496_P050-Biotin)
Sign In for Pricing
View Details 123682-ML650 100 µL
ATG7 (APG7L, Ubiquitin-like Modifier-activating Enzyme ATG7, ATG12-activating Enzyme E1 ATG7, Autophagy-related Protein 7, Ubiquitin-activating Enzyme E1-like Protein) (MaxLight 650)
Sign In for Pricing
View Details